PROFESSIONAL EDITION

The largest community of pharma leaders

Adamas Announces Settlement of Patent Litigation with Zydus

EMERYVILLE, Calif.–(BUSINESS WIRE)–Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles